Loading...
Loading...
PURPLE BIOTECH LTD.
PURPLE BIOTECH LTD.. Spoken Alpha tracks PPBT's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks PPBT's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PPBT.
curl https://api.spokenalpha.com/v1/companies/PPBT| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.71 | $1.70 | +0.5% | +1.9% | +1.1% |
| Q4 FY2026 | $2.00 | $1.87 | +6.8% | +7.6% | +7.9% |
| Q3 FY2026 | $1.87 | $1.80 | +4.1% | +5.8% | +8.3% |
| Q2 FY2026 | $2.12 | $1.96 | +8.4% | +5.7% | +7.3% |
| Q1 FY2025 | $2.06 | $2.07 | -0.7% | -0.3% | +2.3% |
| Q4 FY2025 | $2.13 | $1.96 | +8.6% | +6.8% | +6.0% |
| Q3 FY2025 | $2.06 | $2.06 | +0.2% | -0.3% | -1.7% |
| Q2 FY2025 | $1.89 | $1.95 | -3.2% | +8.4% | +6.4% |
| Q1 FY2024 | $2.08 | $2.00 | +3.8% | +0.1% | +2.5% |
| Q4 FY2024 | $2.28 | $2.15 | +6.0% | +6.7% | +5.9% |